UROV News and Press, Urovant Sciences Ltd. From 09/08/20

Urovant Sciences' ( UROV ) share price has been hit through the coronavirus in 2020 and has not been rising despite the company expecting approval for its main asset Vibegron on December 26, 2020. Furthermore, with sell-side consensus with potential sales peak over $600 M and an overseeable ...

Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being h...

Image source: The Motley Fool. UROVANT SCIENCES LTD   (NASDAQ: UROV) Q1 2020 Earnings Call Aug 13, 2020 , 4:30 p.m. ET Operator Continue reading

Urovant Sciences Ltd. (UROV) Q1 2020 Earnings Conference Call August 13, 2020, 04:30 PM ET Company Participants Ryan Kubota - Executive Director, IR James Robinson - President and CEO Cornelia Haag-Molkenteller - Chief Medical Officer Ajay Bansal - CFO Christine Ocampo - CAO ...

Urovant Sciences (NASDAQ: UROV ) : FQ1 GAAP EPS of -$0.99 beats by $0.37 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access tea...

Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacif...

Urovant Sciences Ltd (UROV) Q4 2019 Earnings Conference Call June 18, 2020, 16:30 ET Company Participants Ryan Kubota - Executive Director, IR James Robinson - Principal Executive Officer & Director Cornelia Haag-Molkenteller - Chief Medical Officer, USI Ajay Bansal - CFO &...

Urovant Sciences (NASDAQ: UROV ): Q4 GAAP EPS of -$1.68 misses by $0.56 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020. The fiscal fourth quarter of 2019 marked achievement of key milestones for Urovant Sciences, including publication of results from the international EMPOWUR P...